{
 "name": "Psilocybin clinical trials with a site in New York State",
 "description": "Every interventional psilocybin study on ClinicalTrials.gov with at least one site in New York State: status, conditions, sponsor, New York sites, enrollment and dates.",
 "publisher": "Mushrooms New York",
 "url": "https://mushroomsnewyork.com/psilocybin-clinical-trials-new-york",
 "license": "CC BY 4.0",
 "license_url": "https://creativecommons.org/licenses/by/4.0/",
 "updated": "2026-11-03",
 "record_count": 30,
 "source_note": "Compiled from the ClinicalTrials.gov API.",
 "records": [
  {
   "nct": "NCT00957359",
   "title": "Psilocybin Cancer Anxiety Study",
   "conditions": [
    "Cancer"
   ],
   "phase": "Early Phase 1",
   "status": "COMPLETED",
   "recruiting": false,
   "sponsor": "NYU Langone Health",
   "ny_sites": [
    {
     "facility": "NYU College of Dentistry Bluestone Center for Clinical Research",
     "city": "New York"
    }
   ],
   "enrollment": 29,
   "enrollment_type": "actual",
   "start": "2009-02",
   "start_type": "actual",
   "primary_completion": "2018-09-06",
   "primary_completion_type": "actual",
   "min_age": "18 Years",
   "max_age": "76 Years",
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT00957359",
   "condition_group": "Cancer-related distress or pain",
   "ny_institutions": [
    "NYU Langone Health"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2020-10-20",
   "notes": "Published: Ross et al., J Psychopharmacol 2016, PMID 27909164; long-term follow-up PMID 31916890."
  },
  {
   "nct": "NCT02061293",
   "title": "A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence",
   "conditions": [
    "Alcohol Dependence"
   ],
   "phase": "Phase 2",
   "status": "COMPLETED",
   "recruiting": false,
   "sponsor": "NYU Langone Health",
   "ny_sites": [
    {
     "facility": "Clinical and Translational Science Institute, NYU Langone Medical Center",
     "city": "New York"
    }
   ],
   "enrollment": 95,
   "enrollment_type": "actual",
   "start": "2014-06",
   "start_type": "actual",
   "primary_completion": "2021-07-30",
   "primary_completion_type": "actual",
   "min_age": "25 Years",
   "max_age": "65 Years",
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT02061293",
   "condition_group": "Substance use (alcohol, tobacco, opioids)",
   "ny_institutions": [
    "NYU Langone Health"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2022-11-08",
   "notes": "Published: Bogenschutz et al., JAMA Psychiatry 2022, PMID 36001306; open-label extension PMID 42913354.; Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT02421263",
   "title": "The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals",
   "conditions": [
    "Religious or Spiritual Problem"
   ],
   "phase": "Phase 1",
   "status": "COMPLETED",
   "recruiting": false,
   "sponsor": "NYU Langone Health",
   "ny_sites": [
    {
     "facility": "NYU Langone Medical Center/Tisch Hospital",
     "city": "New York"
    }
   ],
   "enrollment": 12,
   "enrollment_type": "actual",
   "start": "2015-04",
   "start_type": "actual",
   "primary_completion": "2020-06-05",
   "primary_completion_type": "actual",
   "min_age": "25 Years",
   "max_age": "76 Years",
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT02421263",
   "condition_group": "Other (BDD, IBS, stuttering, clergy, healthy older adults)",
   "ny_institutions": [
    "NYU Langone Health"
   ],
   "sex": "ALL",
   "healthy_volunteers": true,
   "registry_last_updated": "2022-02-14",
   "notes": "Registry enrollment (12) is the NYU arm only; the published clergy study (PMID 41869007) reports 29 randomized across Johns Hopkins and NYU."
  },
  {
   "nct": "NCT03775200",
   "title": "The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression",
   "conditions": [
    "Treatment Resistant Depression"
   ],
   "phase": "Phase 2",
   "status": "COMPLETED",
   "recruiting": false,
   "sponsor": "COMPASS Pathways",
   "ny_sites": [
    {
     "facility": "New York State Psychiatric Institute",
     "city": "New York"
    }
   ],
   "enrollment": 233,
   "enrollment_type": "actual",
   "start": "2019-03-01",
   "start_type": "actual",
   "primary_completion": "2021-07-30",
   "primary_completion_type": "actual",
   "min_age": "18 Years",
   "max_age": null,
   "drug": "psilocybin (COMP360)",
   "url": "https://clinicaltrials.gov/study/NCT03775200",
   "condition_group": "Depression",
   "ny_institutions": [
    "New York State Psychiatric Institute (Columbia)"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2023-04-24",
   "notes": "Published: Goodwin et al., NEJM 2022, PMID 36322843.; Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT03866174",
   "title": "A Study of Psilocybin for Major Depressive Disorder (MDD)",
   "conditions": [
    "Depressive Disorder, Major"
   ],
   "phase": "Phase 2",
   "status": "COMPLETED",
   "recruiting": false,
   "sponsor": "Usona Institute",
   "ny_sites": [
    {
     "facility": "New York University School of Medicine",
     "city": "New York"
    }
   ],
   "enrollment": 347,
   "enrollment_type": "actual",
   "start": "2020-01-23",
   "start_type": "actual",
   "primary_completion": "2022-06-28",
   "primary_completion_type": "actual",
   "min_age": "21 Years",
   "max_age": "65 Years",
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT03866174",
   "condition_group": "Depression",
   "ny_institutions": [
    "NYU Langone Health"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-04-22",
   "notes": "Published: Raison et al., JAMA 2023, PMID 37651119.; Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT04656301",
   "title": "Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder",
   "conditions": [
    "Body Dysmorphic Disorders"
   ],
   "phase": "Phase 2",
   "status": "COMPLETED",
   "recruiting": false,
   "sponsor": "New York State Psychiatric Institute",
   "ny_sites": [
    {
     "facility": "New York State Psychiatric Institute, 1051 Riverside Drive",
     "city": "New York"
    }
   ],
   "enrollment": 12,
   "enrollment_type": "actual",
   "start": "2021-02-26",
   "start_type": "actual",
   "primary_completion": "2022-11-02",
   "primary_completion_type": "actual",
   "min_age": "18 Years",
   "max_age": "55 Years",
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT04656301",
   "condition_group": "Other (BDD, IBS, stuttering, clergy, healthy older adults)",
   "ny_institutions": [
    "New York State Psychiatric Institute (Columbia)"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2023-03-13",
   "notes": "Published: Schneier et al., J Psychiatr Res 2023, PMID 37004409."
  },
  {
   "nct": "NCT05312151",
   "title": "The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder",
   "conditions": [
    "Post Traumatic Stress Disorder"
   ],
   "phase": "Phase 2",
   "status": "COMPLETED",
   "recruiting": false,
   "sponsor": "COMPASS Pathways",
   "ny_sites": [
    {
     "facility": "Icahn School of Medicine at Mount Sinai",
     "city": "New York"
    }
   ],
   "enrollment": 22,
   "enrollment_type": "actual",
   "start": "2022-06-10",
   "start_type": "actual",
   "primary_completion": "2024-02-12",
   "primary_completion_type": "actual",
   "min_age": "18 Years",
   "max_age": null,
   "drug": "psilocybin (COMP360)",
   "url": "https://clinicaltrials.gov/study/NCT05312151",
   "condition_group": "PTSD and trauma",
   "ny_institutions": [
    "Mount Sinai (Icahn School of Medicine)"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2025-06-13",
   "notes": "Published: McGowan et al., J Psychopharmacol 2026, PMID 40883964.; Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT05398484",
   "title": "Psilocybin Therapy in Advanced Cancer",
   "conditions": [
    "Advanced Cancer"
   ],
   "phase": "Phase 2/Phase 3",
   "status": "RECRUITING",
   "recruiting": true,
   "sponsor": "NYU Langone Health",
   "ny_sites": [
    {
     "facility": "NYU Langone Health",
     "city": "New York"
    }
   ],
   "enrollment": 200,
   "enrollment_type": "anticipated",
   "start": "2023-05-24",
   "start_type": "actual",
   "primary_completion": "2027-01-01",
   "primary_completion_type": "estimated",
   "min_age": "21 Years",
   "max_age": "100 Years",
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT05398484",
   "condition_group": "Cancer-related distress or pain",
   "ny_institutions": [
    "NYU Langone Health"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-10-14",
   "notes": "NY site-level status on registry: NYU Langone Health (New York): RECRUITING; Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT05452772",
   "title": "5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder",
   "conditions": [
    "Tobacco Use Disorder"
   ],
   "phase": "Phase 2",
   "status": "RECRUITING",
   "recruiting": false,
   "sponsor": "Johns Hopkins University",
   "ny_sites": [
    {
     "facility": "New York University",
     "city": "New York"
    }
   ],
   "enrollment": 66,
   "enrollment_type": "anticipated",
   "start": "2023-11-01",
   "start_type": "actual",
   "primary_completion": "2026-12",
   "primary_completion_type": "estimated",
   "min_age": "21 Years",
   "max_age": null,
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT05452772",
   "condition_group": "Substance use (alcohol, tobacco, opioids)",
   "ny_institutions": [
    "NYU Langone Health"
   ],
   "sex": "ALL",
   "healthy_volunteers": true,
   "registry_last_updated": "2026-06-29",
   "notes": "NY site-level status on registry: New York University (New York): ACTIVE_NOT_RECRUITING; Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT05624268",
   "title": "Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD",
   "conditions": [
    "Treatment Resistant Depression"
   ],
   "phase": "Phase 3",
   "status": "COMPLETED",
   "recruiting": false,
   "sponsor": "COMPASS Pathways",
   "ny_sites": [
    {
     "facility": "New York State Psychiatric Institute",
     "city": "New York"
    },
    {
     "facility": "The Medical Research Network, LLC",
     "city": "New York"
    }
   ],
   "enrollment": 258,
   "enrollment_type": "actual",
   "start": "2023-01-24",
   "start_type": "actual",
   "primary_completion": "2025-05-28",
   "primary_completion_type": "actual",
   "min_age": "18 Years",
   "max_age": null,
   "drug": "psilocybin (COMP360)",
   "url": "https://clinicaltrials.gov/study/NCT05624268",
   "condition_group": "Depression",
   "ny_institutions": [
    "New York State Psychiatric Institute (Columbia)",
    "The Medical Research Network, LLC"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-08-10",
   "notes": "Phase 3 COMP005. Sponsor-reported topline: MADRS difference -3.6 vs placebo at week 6, p<0.001, n=258 (Compass release, 2026-02-17).; Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT05711940",
   "title": "Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD",
   "conditions": [
    "Treatment Resistant Depression"
   ],
   "phase": "Phase 3",
   "status": "ACTIVE_NOT_RECRUITING",
   "recruiting": false,
   "sponsor": "COMPASS Pathways",
   "ny_sites": [
    {
     "facility": "Dent Neurosciences Research Center, Inc.",
     "city": "Amherst"
    },
    {
     "facility": "Fieve Clinical Research, Inc",
     "city": "New York"
    },
    {
     "facility": "Spectrum Neuroscience and Treatment Institute",
     "city": "New York"
    },
    {
     "facility": "Adams Clinical - New York",
     "city": "New York"
    },
    {
     "facility": "New York State Psychiatric Institute",
     "city": "New York"
    },
    {
     "facility": "Richmond Behavioral Associates",
     "city": "Staten Island"
    },
    {
     "facility": "Adams Clinical - New York",
     "city": "The Bronx"
    }
   ],
   "enrollment": 572,
   "enrollment_type": "actual",
   "start": "2023-02-14",
   "start_type": "actual",
   "primary_completion": "2025-11-13",
   "primary_completion_type": "actual",
   "min_age": "18 Years",
   "max_age": null,
   "drug": "psilocybin (COMP360)",
   "url": "https://clinicaltrials.gov/study/NCT05711940",
   "condition_group": "Depression",
   "ny_institutions": [
    "Adams Clinical (Manhattan and Bronx)",
    "Dent Neurosciences Research Center, Inc.",
    "Fieve Clinical Research, Inc",
    "New York State Psychiatric Institute (Columbia)",
    "Richmond Behavioral Associates",
    "Spectrum Neuroscience and Treatment Institute"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-08-10",
   "notes": "Phase 3 COMP006. Sponsor-reported topline: MADRS difference -3.8 (25 mg vs 1 mg) at week 6, p<0.001, n=581 dosed (Compass release, 2026-02-17).; Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT06308653",
   "title": "Psilocybin for Major Depressive Disorder (MDD)",
   "conditions": [
    "Depressive Disorder, Major"
   ],
   "phase": "Phase 3",
   "status": "ACTIVE_NOT_RECRUITING",
   "recruiting": false,
   "sponsor": "Usona Institute",
   "ny_sites": [
    {
     "facility": "NYU Clinical & Translational Science Institute",
     "city": "New York"
    },
    {
     "facility": "Bronx Veterans Research Foundation at the James J. Peters VAMC",
     "city": "The Bronx"
    }
   ],
   "enrollment": 238,
   "enrollment_type": "actual",
   "start": "2024-03-13",
   "start_type": "actual",
   "primary_completion": "2026-01-05",
   "primary_completion_type": "actual",
   "min_age": "18 Years",
   "max_age": null,
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT06308653",
   "condition_group": "Depression",
   "ny_institutions": [
    "James J. Peters VA Medical Center (Bronx)",
    "NYU Langone Health"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-10-21",
   "notes": "Phase 3 uAspire (PSIL301). Usona reports enrollment completed November 2025 at 30 US sites (impact.usonainstitute.org/drug-development-2025).; Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT06342310",
   "title": "RE104 Safety and Efficacy Study in Postpartum Depression",
   "conditions": [
    "Postpartum Depression"
   ],
   "phase": "Phase 2",
   "status": "COMPLETED",
   "recruiting": false,
   "sponsor": "Reunion Neuroscience Inc",
   "ny_sites": [
    {
     "facility": "Reunion Investigational Site",
     "city": "Buffalo"
    },
    {
     "facility": "Reunion Investigational Site",
     "city": "New York"
    },
    {
     "facility": "Reunion Investigational Site",
     "city": "New York"
    }
   ],
   "enrollment": 84,
   "enrollment_type": "actual",
   "start": "2024-06-14",
   "start_type": "actual",
   "primary_completion": "2025-05-22",
   "primary_completion_type": "actual",
   "min_age": "18 Years",
   "max_age": "45 Years",
   "drug": "RE104 (prodrug of 4-OH-DiPT, a psilocin analog)",
   "url": "https://clinicaltrials.gov/study/NCT06342310",
   "condition_group": "Depression",
   "ny_institutions": [
    "Unnamed Reunion investigational site"
   ],
   "sex": "FEMALE",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-05-14",
   "notes": "NY facility names hidden on the registry (\"Reunion Investigational Site\" in Buffalo and two in New York).; Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT06349083",
   "title": "Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD",
   "conditions": [
    "Alcohol Use Disorder"
   ],
   "phase": "Phase 2",
   "status": "RECRUITING",
   "recruiting": true,
   "sponsor": "NYU Langone Health",
   "ny_sites": [
    {
     "facility": "NYU Langone Health",
     "city": "New York"
    }
   ],
   "enrollment": 200,
   "enrollment_type": "anticipated",
   "start": "2026-09-01",
   "start_type": "estimated",
   "primary_completion": "2030-05",
   "primary_completion_type": "estimated",
   "min_age": "18 Years",
   "max_age": "65 Years",
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT06349083",
   "condition_group": "Substance use (alcohol, tobacco, opioids)",
   "ny_institutions": [
    "NYU Langone Health"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-09-02",
   "notes": "NY site-level status on registry: NYU Langone Health (New York): RECRUITING"
  },
  {
   "nct": "NCT06564818",
   "title": "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder",
   "conditions": [
    "Major Depressive Disorder"
   ],
   "phase": "Phase 3",
   "status": "COMPLETED",
   "recruiting": false,
   "sponsor": "Cybin IRL Limited",
   "ny_sites": [
    {
     "facility": "Adams Clinical Harlem",
     "city": "New York"
    },
    {
     "facility": "Adams Clinical Bronx",
     "city": "The Bronx"
    }
   ],
   "enrollment": 223,
   "enrollment_type": "actual",
   "start": "2024-12-17",
   "start_type": "actual",
   "primary_completion": "2026-09-04",
   "primary_completion_type": "actual",
   "min_age": "18 Years",
   "max_age": "85 Years",
   "drug": "CYB003 (deuterated psilocin analog)",
   "url": "https://clinicaltrials.gov/study/NCT06564818",
   "condition_group": "Depression",
   "ny_institutions": [
    "Adams Clinical (Manhattan and Bronx)"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-10-27",
   "notes": "Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT06592833",
   "title": "Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder",
   "conditions": [
    "Major Depressive Disorder"
   ],
   "phase": "Phase 2",
   "status": "RECRUITING",
   "recruiting": true,
   "sponsor": "Icahn School of Medicine at Mount Sinai",
   "ny_sites": [
    {
     "facility": "Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research",
     "city": "New York"
    }
   ],
   "enrollment": 60,
   "enrollment_type": "anticipated",
   "start": "2025-02-25",
   "start_type": "actual",
   "primary_completion": "2028-03-01",
   "primary_completion_type": "estimated",
   "min_age": "21 Years",
   "max_age": "80 Years",
   "drug": "psilocybin (alone vs with pimavanserin)",
   "url": "https://clinicaltrials.gov/study/NCT06592833",
   "condition_group": "Depression",
   "ny_institutions": [
    "Mount Sinai (Icahn School of Medicine)"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2025-05-14",
   "notes": "NY site-level status on registry: Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research (New York): RECRUITING; Registry record last updated 2025-05-14; recruiting status may be stale. Confirm with site before relying on it."
  },
  {
   "nct": "NCT06605105",
   "title": "Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)",
   "conditions": [
    "Major Depressive Disorder"
   ],
   "phase": "Phase 3",
   "status": "ENROLLING_BY_INVITATION",
   "recruiting": false,
   "sponsor": "Cybin IRL Limited",
   "ny_sites": [
    {
     "facility": "Adams Clinical Harlem",
     "city": "New York"
    },
    {
     "facility": "Adams Clinical Bronx",
     "city": "The Bronx"
    }
   ],
   "enrollment": 468,
   "enrollment_type": "anticipated",
   "start": "2025-07-18",
   "start_type": "actual",
   "primary_completion": "2028-06-06",
   "primary_completion_type": "estimated",
   "min_age": "18 Years",
   "max_age": "85 Years",
   "drug": "CYB003 (deuterated psilocin analog)",
   "url": "https://clinicaltrials.gov/study/NCT06605105",
   "condition_group": "Depression",
   "ny_institutions": [
    "Adams Clinical (Manhattan and Bronx)"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-09-25",
   "notes": "Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT06760533",
   "title": "Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)",
   "conditions": [
    "IBS - Irritable Bowel Syndrome"
   ],
   "phase": "Early Phase 1",
   "status": "NOT_YET_RECRUITING",
   "recruiting": false,
   "sponsor": "NYU Langone Health",
   "ny_sites": [
    {
     "facility": "NYU Langone Health",
     "city": "New York"
    }
   ],
   "enrollment": 10,
   "enrollment_type": "anticipated",
   "start": "2026-08",
   "start_type": "estimated",
   "primary_completion": "2026-12",
   "primary_completion_type": "estimated",
   "min_age": "18 Years",
   "max_age": "75 Years",
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT06760533",
   "condition_group": "Other (BDD, IBS, stuttering, clergy, healthy older adults)",
   "ny_institutions": [
    "NYU Langone Health"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-03-05",
   "notes": "Estimated start (2026-08) has passed but status is still NOT_YET_RECRUITING (record last updated 2026-03-05); may be stale."
  },
  {
   "nct": "NCT06793397",
   "title": "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder",
   "conditions": [
    "Major Depressive Disorder (MDD)",
    "Depression in Adults",
    "Depression - Major Depressive Disorder",
    "Depression Disorders",
    "Depression Disorder",
    "Depression"
   ],
   "phase": "Phase 3",
   "status": "RECRUITING",
   "recruiting": true,
   "sponsor": "Cybin IRL Limited",
   "ny_sites": [
    {
     "facility": "Adams Clinical Harlem",
     "city": "New York"
    },
    {
     "facility": "New York State Psychiatric Institute",
     "city": "New York"
    },
    {
     "facility": "Adams Clinical Bronx",
     "city": "The Bronx"
    }
   ],
   "enrollment": 330,
   "enrollment_type": "anticipated",
   "start": "2025-12-10",
   "start_type": "actual",
   "primary_completion": "2027-06-07",
   "primary_completion_type": "estimated",
   "min_age": "18 Years",
   "max_age": "85 Years",
   "drug": "CYB003 (deuterated psilocin analog)",
   "url": "https://clinicaltrials.gov/study/NCT06793397",
   "condition_group": "Depression",
   "ny_institutions": [
    "Adams Clinical (Manhattan and Bronx)",
    "New York State Psychiatric Institute (Columbia)"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-11-02",
   "notes": "NY site-level status on registry: Adams Clinical Harlem (New York): RECRUITING; New York State Psychiatric Institute (New York): NOT_YET_RECRUITING; Adams Clinical Bronx (The Bronx): RECRUITING; Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT06796062",
   "title": "Psilocybin for Opioid Use Disorder (OUD)",
   "conditions": [
    "Opioid Use Disorder"
   ],
   "phase": "Phase 2",
   "status": "RECRUITING",
   "recruiting": true,
   "sponsor": "NYU Langone Health",
   "ny_sites": [
    {
     "facility": "StartCare",
     "city": "Brooklyn"
    },
    {
     "facility": "NYU Langone Health",
     "city": "New York"
    },
    {
     "facility": "VIP Community Services, Inc",
     "city": "The Bronx"
    }
   ],
   "enrollment": 480,
   "enrollment_type": "anticipated",
   "start": "2025-12-17",
   "start_type": "actual",
   "primary_completion": "2029-02",
   "primary_completion_type": "estimated",
   "min_age": "18 Years",
   "max_age": "65 Years",
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT06796062",
   "condition_group": "Substance use (alcohol, tobacco, opioids)",
   "ny_institutions": [
    "NYU Langone Health",
    "StartCare",
    "VIP Community Services, Inc"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-01-23",
   "notes": "NY site-level status on registry: StartCare (Brooklyn): RECRUITING; NYU Langone Health (New York): RECRUITING; VIP Community Services, Inc (The Bronx): RECRUITING; Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT06827054",
   "title": "Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids",
   "conditions": [
    "Hematopoietic and Lymphatic System Neoplasm",
    "Malignant Solid Neoplasm"
   ],
   "phase": "Phase 2",
   "status": "NOT_YET_RECRUITING",
   "recruiting": false,
   "sponsor": "Roswell Park Cancer Institute",
   "ny_sites": [
    {
     "facility": "Roswell Park Cancer Institute",
     "city": "Buffalo"
    }
   ],
   "enrollment": 20,
   "enrollment_type": "anticipated",
   "start": "2026-09-15",
   "start_type": "estimated",
   "primary_completion": "2027-05-05",
   "primary_completion_type": "estimated",
   "min_age": "18 Years",
   "max_age": "75 Years",
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT06827054",
   "condition_group": "Cancer-related distress or pain",
   "ny_institutions": [
    "Roswell Park Comprehensive Cancer Center (Buffalo)"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-08-12",
   "notes": "Estimated start (2026-09-15) has passed but status is still NOT_YET_RECRUITING; Roswell Park calls it low-dose psilocybin in the official title."
  },
  {
   "nct": "NCT06899165",
   "title": "Psilocybin-Assisted Therapy for Intergenerational Trauma",
   "conditions": [
    "Psychological Stress",
    "Depression",
    "Anxiety"
   ],
   "phase": "Phase 2",
   "status": "RECRUITING",
   "recruiting": true,
   "sponsor": "Rachel Yehuda",
   "ny_sites": [
    {
     "facility": "The Parsons Research Center for Psychedelic Healing",
     "city": "New York"
    }
   ],
   "enrollment": 100,
   "enrollment_type": "anticipated",
   "start": "2026-08-28",
   "start_type": "estimated",
   "primary_completion": "2029-05-31",
   "primary_completion_type": "estimated",
   "min_age": "18 Years",
   "max_age": null,
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT06899165",
   "condition_group": "PTSD and trauma",
   "ny_institutions": [
    "Mount Sinai (Icahn School of Medicine)"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-08-13",
   "notes": "NY site-level status on registry: The Parsons Research Center for Psychedelic Healing (New York): RECRUITING"
  },
  {
   "nct": "NCT07002034",
   "title": "RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses",
   "conditions": [
    "Adjustment Disorder"
   ],
   "phase": "Phase 2",
   "status": "RECRUITING",
   "recruiting": true,
   "sponsor": "Reunion Neuroscience Inc",
   "ny_sites": [
    {
     "facility": "Roswell Park Center Institute",
     "city": "Buffalo"
    },
    {
     "facility": "NYU Langone Health",
     "city": "New York"
    }
   ],
   "enrollment": 100,
   "enrollment_type": "anticipated",
   "start": "2025-07-30",
   "start_type": "actual",
   "primary_completion": "2026-11",
   "primary_completion_type": "estimated",
   "min_age": "18 Years",
   "max_age": "80 Years",
   "drug": "RE104 (prodrug of 4-OH-DiPT, a psilocin analog)",
   "url": "https://clinicaltrials.gov/study/NCT07002034",
   "condition_group": "Cancer-related distress or pain",
   "ny_institutions": [
    "NYU Langone Health",
    "Roswell Park Comprehensive Cancer Center (Buffalo)"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-09-15",
   "notes": "NY site-level status on registry: Roswell Park Center Institute (Buffalo): RECRUITING; NYU Langone Health (New York): RECRUITING; Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT07251491",
   "title": "Psilocybin to Treat Depression in Spinal Cord Injury",
   "conditions": [
    "Spinal Cord Injury",
    "Depression - Major Depressive Disorder",
    "Veteran"
   ],
   "phase": "Phase 1/Phase 2",
   "status": "RECRUITING",
   "recruiting": true,
   "sponsor": "James J. Peters Veterans Affairs Medical Center",
   "ny_sites": [
    {
     "facility": "James J. Peters Department of Veterans Affairs Medical Center",
     "city": "The Bronx"
    }
   ],
   "enrollment": 30,
   "enrollment_type": "anticipated",
   "start": "2026-08-06",
   "start_type": "actual",
   "primary_completion": "2028-03-01",
   "primary_completion_type": "estimated",
   "min_age": "22 Years",
   "max_age": null,
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT07251491",
   "condition_group": "Depression",
   "ny_institutions": [
    "James J. Peters VA Medical Center (Bronx)"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-08-10",
   "notes": "NY site-level status on registry: James J. Peters Department of Veterans Affairs Medical Center (The Bronx): RECRUITING"
  },
  {
   "nct": "NCT07296328",
   "title": "Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter",
   "conditions": [
    "Stuttering"
   ],
   "phase": "Phase 2",
   "status": "NOT_YET_RECRUITING",
   "recruiting": false,
   "sponsor": "NYU Langone Health",
   "ny_sites": [
    {
     "facility": "NYU Langone Health",
     "city": "New York"
    }
   ],
   "enrollment": 25,
   "enrollment_type": "anticipated",
   "start": "2026-01-15",
   "start_type": "estimated",
   "primary_completion": "2027-04-01",
   "primary_completion_type": "estimated",
   "min_age": "18 Years",
   "max_age": "50 Years",
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT07296328",
   "condition_group": "Other (BDD, IBS, stuttering, clergy, healthy older adults)",
   "ny_institutions": [
    "NYU Langone Health"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2025-12-22",
   "notes": "Estimated start (2026-01-15) has passed but status is still NOT_YET_RECRUITING (record last updated 2025-12-22); may be stale."
  },
  {
   "nct": "NCT07489651",
   "title": "RE104 Safety and Efficacy Study in Generalized Anxiety Disorder",
   "conditions": [
    "Generalized Anxiety Disorder"
   ],
   "phase": "Phase 2",
   "status": "RECRUITING",
   "recruiting": true,
   "sponsor": "Reunion Neuroscience Inc",
   "ny_sites": [
    {
     "facility": "NYU-H+C Clinical and Translational Science Institute",
     "city": "New York"
    }
   ],
   "enrollment": 160,
   "enrollment_type": "anticipated",
   "start": "2026-04-20",
   "start_type": "actual",
   "primary_completion": "2027-07",
   "primary_completion_type": "estimated",
   "min_age": "18 Years",
   "max_age": "74 Years",
   "drug": "RE104 (prodrug of 4-OH-DiPT, a psilocin analog)",
   "url": "https://clinicaltrials.gov/study/NCT07489651",
   "condition_group": "Generalized anxiety disorder",
   "ny_institutions": [
    "NYU Langone Health"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-09-24",
   "notes": "NY site-level status on registry: NYU-H+C Clinical and Translational Science Institute (New York): RECRUITING; Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT07516405",
   "title": "Safety and Tolerability Trial of Psilocybin in Healthy Older Adults",
   "conditions": [
    "Healthy Volunteer",
    "Older Adults (65-85 Years)"
   ],
   "phase": "Phase 1",
   "status": "RECRUITING",
   "recruiting": true,
   "sponsor": "University of Colorado, Denver",
   "ny_sites": [
    {
     "facility": "New York University Langone Health, Center for Psychedelic Medicine",
     "city": "New York"
    }
   ],
   "enrollment": 40,
   "enrollment_type": "anticipated",
   "start": "2026-04-01",
   "start_type": "actual",
   "primary_completion": "2028-03",
   "primary_completion_type": "estimated",
   "min_age": "65 Years",
   "max_age": "85 Years",
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT07516405",
   "condition_group": "Other (BDD, IBS, stuttering, clergy, healthy older adults)",
   "ny_institutions": [
    "NYU Langone Health"
   ],
   "sex": "ALL",
   "healthy_volunteers": true,
   "registry_last_updated": "2026-09-16",
   "notes": "NY site-level status on registry: New York University Langone Health, Center for Psychedelic Medicine (New York): RECRUITING; Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT07570654",
   "title": "Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder",
   "conditions": [
    "PTSD - Post Traumatic Stress Disorder",
    "PTSD",
    "PTSD Symptoms",
    "PTSD, Post Traumatic Stress Disorder"
   ],
   "phase": "Phase 2/Phase 3",
   "status": "RECRUITING",
   "recruiting": true,
   "sponsor": "COMPASS Pathways",
   "ny_sites": [
    {
     "facility": "NY",
     "city": "New York"
    },
    {
     "facility": "NY",
     "city": "The Bronx"
    }
   ],
   "enrollment": 300,
   "enrollment_type": "anticipated",
   "start": "2026-09",
   "start_type": "estimated",
   "primary_completion": "2028-11",
   "primary_completion_type": "estimated",
   "min_age": "18 Years",
   "max_age": null,
   "drug": "psilocybin (COMP360)",
   "url": "https://clinicaltrials.gov/study/NCT07570654",
   "condition_group": "PTSD and trauma",
   "ny_institutions": [
    "Unnamed site listed only as \"NY\""
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-10-23",
   "notes": "NY site-level status on registry: NY (New York): RECRUITING; NY (The Bronx): RECRUITING; NY facility names are hidden on the registry (listed only as \"NY\", New York and The Bronx). Estimated start 2026-09.; Enrollment is the whole trial across all sites, not New York only."
  },
  {
   "nct": "NCT07607938",
   "title": "Psilocybin as a Novel Therapy for Residual Anhedonia",
   "conditions": [
    "Anhedonia",
    "Emotional Blunting"
   ],
   "phase": "Phase 1",
   "status": "RECRUITING",
   "recruiting": true,
   "sponsor": "NYU Langone Health",
   "ny_sites": [
    {
     "facility": "NYU Langone Health",
     "city": "New York"
    }
   ],
   "enrollment": 90,
   "enrollment_type": "anticipated",
   "start": "2026-09",
   "start_type": "estimated",
   "primary_completion": "2030-08-01",
   "primary_completion_type": "estimated",
   "min_age": "18 Years",
   "max_age": "65 Years",
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT07607938",
   "condition_group": "Depression",
   "ny_institutions": [
    "NYU Langone Health"
   ],
   "sex": "ALL",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-09-15",
   "notes": "NY site-level status on registry: NYU Langone Health (New York): RECRUITING"
  },
  {
   "nct": "NCT07909408",
   "title": "Psilocybin FCR Early-Stage Breast Cancer",
   "conditions": [
    "Early-stage Breast Cancer",
    "Fear of Cancer Recurrence",
    "Anxiety",
    "Depression"
   ],
   "phase": "Phase 2",
   "status": "NOT_YET_RECRUITING",
   "recruiting": false,
   "sponsor": "NYU Langone Health",
   "ny_sites": [
    {
     "facility": "NYU Langone Heath",
     "city": "New York"
    }
   ],
   "enrollment": 100,
   "enrollment_type": "anticipated",
   "start": "2027-01-02",
   "start_type": "estimated",
   "primary_completion": "2031-01-02",
   "primary_completion_type": "estimated",
   "min_age": "21 Years",
   "max_age": null,
   "drug": "psilocybin",
   "url": "https://clinicaltrials.gov/study/NCT07909408",
   "condition_group": "Cancer-related distress or pain",
   "ny_institutions": [
    "NYU Langone Health"
   ],
   "sex": "FEMALE",
   "healthy_volunteers": false,
   "registry_last_updated": "2026-11-02",
   "notes": "Enrollment is the whole trial across all sites, not New York only."
  }
 ]
}